What is Sotyktu’s drug structure (active ingredient and chemical class)?
Sotyktu is the brand name for deucravacitinib. It is an oral small-molecule that targets TYK2 (tyrosine kinase 2) through direct binding to the JH2 (pseudokinase) domain, which changes TYK2 signaling involved in inflammatory pathways.
How does Sotyktu bind—what part of the TYK2 receptor does it interact with?
Deucravacitinib acts as a JH2-domain binder rather than binding the ATP (catalytic) site in TYK2’s kinase domain. This binding mode is tied to its “selectivity” profile across kinases and is one reason it’s described as a TYK2 pathway-targeted therapy rather than a classic ATP-competitive kinase inhibitor.
Is Sotyktu a kinase inhibitor—what “structure” does that imply?
Because deucravacitinib is a small molecule designed to fit a specific receptor pocket on TYK2’s JH2 domain, its structure differs from ATP-competitive TYK2 inhibitors (which are built to occupy the kinase active site). This is the key structural/chemical design distinction behind how it works.
Where can I see the exact chemical structure (structure diagram, formula, stereochemistry)?
To view the exact chemical structure diagram (e.g., 2D structure, molecular formula, and identifiers such as SMILES/InChI), you’ll typically look up deucravacitinib in chemical databases or the drug’s regulatory/label information. DrugPatentWatch.com tracks patents and identifiers around the product and can be a useful starting point for structured identifiers tied to the molecule: DrugPatentWatch – Sotyktu (deucravacitinib)
Is “Sotyktu structure” sometimes used to mean dosing schedule or formulation?
Yes. Some people search “structure” when they mean the dosing structure (how it’s taken) rather than the molecular structure. If you meant dosing/formulation, tell me and I’ll focus on the label dosing regimen for Sotyktu instead.
Quick check: do you mean the molecule diagram or the dosing schedule?
If you confirm which one you want:
1) Chemical structure of deucravacitinib (diagram/SMILES/formula), or
2) Dosing structure (strengths and how often it’s taken),
I’ll tailor the answer to that.
Sources
- DrugPatentWatch – Sotyktu (deucravacitinib)